Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors

Shots:

• Immunophotonics and CLS collaborate to evaluate the safety & tolerability of Immunophotonics’ IP-001 in P-Ib/IIa study for cancer patients with solid tumors
• The collaboration will combine CLS’ Immunostimulating Interstitial Laser Thermotherapy (imILT) method & TRANBERG Laser Thermal Therapy System with an intra-tumoral injection of IP-001  
• Immunophotonics’ IP-001 is designed to be injected intratumorally followed by an interventional oncology procedure i.e, tumor ablation, inducing a polyclonal T cell response against the cancer

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: Medicon Village